|
1. Biologie
|
|
|
|
1.4 Biologie - Technos
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
Positive Results in a Busy Week of Cancer Clinical Studies [OBR]
|
|
|
|
|
|
This
week is turning out to be a busy and exciting week in readouts from
Phase 3 clinical trials, including results from the CheckMate 227 trial
in first-line advanced non-small cell lung cancer; the IMmotion 151
trial in unresectable locally advanced or metastatic renal cell
carcinoma; and the COLUMBUS trial in melanoma.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
Study Identifies Potential Drug Combination for Ewing Sarcoma [NCI]
|
|
|
|
|
|
One
of the drugs, vincristine, is a chemotherapy agent that is part of the
standard treatment for patients with Ewing sarcoma. The other, YK-4-279,
is an experimental drug that targets an abnormality, called a fusion
protein, that is commonly found in Ewing sarcoma tumors.
|
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
Bristol-Myers Squibb Sows Confusion [In the Pipeline]
|
|
|
|
|
|
The
changes to the trial were one issue, the lack of transparency about how
the trial had changed was another, and just the fact that a company
this large, with such an important readout, would have done something
like this was a third.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
Preview Of Key Abstracts From The 2018 ASCO GU Cancers Symposium [OBR]
|
|
|
|
|
|
On
the eve of the 2018 Genitourinary Cancers Symposium to be held in San
Francisco February 8-10, a pre-meeting presscast featured four
noteworthy abstracts: two related to immunotherapy with a PD-L1
inhibitor atezolizumab in urothelial cancers and two to treatment of
non-metastatic advanced prostate cancer.
|
|
|
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
Medical and Patient Groups Warn Congress Against “Right to Try” [Xconomy]
|
|
|
|
|
|
“Our
organizations support patient access to unapproved therapies,” the
letter reads, in part. “However, the right-to-try bills currently under
consideration in the House do not effectuate policy changes that would
afford our patients greater access to promising investigational
therapies. Instead, these bills would likely do more harm than good.”
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
A Festival for Persistent Identifiers [Research Data]
|
|
|
|
|
|
We
need trust in the connections between the things we’re trying to find.
How do we incentivise researchers to use PIDs to link their data
publications to all research outputs? What can we learn from the PID
community that could help drive adoption in the data community?
|
|
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|